AI English summary of an SEC filing — figures as filed
Amgen AMGNAmgen said total product sales increased in 2024, primarily driven by volume growth of 23%, partially offset by declines in net selling price of 2%. Product sales from acquired Horizon products were $4.2 billion in 2024 and $954 million in 2023.
Key points
AI summaryAmgen said total product sales increased in 2024, primarily driven by volume growth of 23%, partially offset by declines in net selling price of 2%. Product sales from acquired Horizon products were $4.2 billion in 2024 and $954 million in 2023.
The company said cash flows from operating activities in 2024 totaled $11.5 billion, which supported capital expenditures of $1.1 billion, payment of cash dividends of $4.8 billion, repayment of debt of $3.6 billion and stock repurchases of $200 million.
Amgen said cost of sales increased to 38.5% of total revenues in 2024, citing higher amortization expense from Horizon acquisition-related assets and, to a lesser extent, higher profit share and royalty expense. Cost of sales was 30.0% of total revenues in 2023.
The company said patents for RANKL antibodies, including sequences, for Prolia and XGEVA expire in February 2025 in the United States and in November 2025 in select countries in Europe. It said it expects sales erosion driven by biosimilar competition in 2025.
Key figures
Fiscal year ended December 31, 2024
- Revenue
- $33.4B
- Operating income
- $7.3B
- Net income
- $4.1B
- EPS
- $7.56
- Operating cash flow
- $11.5B
From the XBRL financial data filed with the SEC · not processed by AI.
Summary
AI-writtenAnalysis scope · Management's discussion (MD&A)We analyzed excerpts of the Management's Discussion and Analysis (MD&A) section (with omissions). Other sections of the report, such as the notes to the financial statements and risk factors, were not reviewed.
2024 Product Sales: Volume Growth of 23%, Horizon Products $4.2 billion
Amgen said total product sales increased in 2024, primarily driven by volume growth of 23%, partially offset by declines in net selling price of 2%. Product sales from acquired Horizon products were $4.2 billion in 2024 and $954 million in 2023.
Source · Based on the MD&A text of the filing
Operating Cash Flow $11.5 billion and Capital Returns
The company said cash flows from operating activities in 2024 totaled $11.5 billion, which supported capital expenditures of $1.1 billion, payment of cash dividends of $4.8 billion, repayment of debt of $3.6 billion and stock repurchases of $200 million.
Source · Based on the MD&A text of the filing
2024 Cost of Sales as 38.5% of Total Revenues
Amgen said cost of sales increased to 38.5% of total revenues in 2024, citing higher amortization expense from Horizon acquisition-related assets and, to a lesser extent, higher profit share and royalty expense. Cost of sales was 30.0% of total revenues in 2023.
Source · Based on the MD&A text of the filing
Prolia and XGEVA Patent Expiration and Expected Sales Erosion in 2025
The company said patents for RANKL antibodies, including sequences, for Prolia and XGEVA expire in February 2025 in the United States and in November 2025 in select countries in Europe. It said it expects sales erosion driven by biosimilar competition in 2025.
Source · Based on the MD&A text of the filing
AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.
Original filing
The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.
Loading the filing text…